NCT04581070

Brief Summary

This is a prospective, multisite, descriptive, observational clinical/epidemiological study examining both quantitative and qualitative data pertaining to clinical outcomes and organizational responses to the 2020 SARS-Coronavirus-2 (SARS-CoV-2) pandemic.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2020

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 29, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 29, 2020

Completed
4 months until next milestone

First Posted

Study publicly available on registry

October 9, 2020

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 9, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 9, 2020

Completed
Last Updated

October 30, 2020

Status Verified

October 1, 2020

Enrollment Period

5 months

First QC Date

May 29, 2020

Last Update Submit

October 28, 2020

Conditions

CancerCOVID-19

Outcome Measures

Primary Outcomes (1)

  • A qualitative description

    A qualitative narrative description of national cancer care practises and risk mitigation strategies adopted in response to the SARS-CoV-2 pandemic.

    Up til 1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients under the care of medical oncology \& malignant haematology services, admitted at participating sites, who test positive for SARS-CoV-2 infection.

You may qualify if:

  • Age ≥ 18
  • Informed consent has been obtained.
  • Cytotoxic chemotherapy, targeted anticancer therapy, immunomodulatory anticancer therapy, hormonotherapy, radiotherapy, oncologic surgery, or other anticancer treatment within the last 12 months (ongoing and completed).
  • Tested positive for SARS-CoV-2.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Mater Misericordiae University Hospital

Dublin, Ireland

Location

University Hospital Limerick

Limerick, Ireland

Location

University Hospital Waterford

Waterford, Ireland

Location

MeSH Terms

Conditions

NeoplasmsCOVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 29, 2020

First Posted

October 9, 2020

Study Start

April 29, 2020

Primary Completion

October 9, 2020

Study Completion

October 9, 2020

Last Updated

October 30, 2020

Record last verified: 2020-10

Locations

IE(3)